» Articles » PMID: 21739043

Miltefosine Induces Programmed Cell Death in Leishmania Amazonensis Promastigotes

Abstract

In the current study, we evaluated the mechanism of action of miltefosine, which is the first effective and safe oral treatment for visceral leishmaniasis, in Leishmania amazonensis promastigotes. Miltefosine induced a process of programmed cell death, which was determined by the externalization of phosphatidylserine, the incorporation of propidium iodide, cell-cycle arrest at the sub-G0/G1 phase and DNA fragmentation into oligonucleosome-sized fragments. Despite the intrinsic variation that is detected in Leishmania spp, our results indicate that miltefosine causes apoptosis-like death in L. amazonensis promastigote cells using a similar process that is observed in Leishmania donovani.

Citing Articles

Epoxy-a-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB/c - Leishmania (Leishmania) amazonensis.

Peixoto J, Goncalves-Oliveira L, Dias-Lopes G, Souza-Silva F, Alves C Mem Inst Oswaldo Cruz. 2024; 119:e240115.

PMID: 39476028 PMC: 11520661. DOI: 10.1590/0074-02760240115.


Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease.

Benaim G, Paniz-Mondolfi A Biomolecules. 2024; 14(4).

PMID: 38672424 PMC: 11047903. DOI: 10.3390/biom14040406.


Evaluation of In Vitro Cytotoxic and Apoptotic Effects of Miltefosine on the RH Strain.

Khademvatan S, Yousefi E, Asadi N, Abasi E Iran J Parasitol. 2024; 19(1):52-60.

PMID: 38654955 PMC: 11033531. DOI: 10.18502/ijpa.v19i1.15204.


Polymeric nanoparticles containing kojic acid induce structural alterations and apoptosis-like death in () .

Queiroz-Souza P, Galue-Parra A, Silveira Moraes L, Macedo C, Rodrigues A, H S Marinho V Front Pharmacol. 2024; 15:1331240.

PMID: 38323082 PMC: 10844493. DOI: 10.3389/fphar.2024.1331240.


Laurequinone, a Lead Compound against .

Garcia-Davis S, Lopez-Arencibia A, Bethencourt-Estrella C, San Nicolas-Hernandez D, Viveros-Valdez E, Diaz-Marrero A Mar Drugs. 2023; 21(6).

PMID: 37367658 PMC: 10304164. DOI: 10.3390/md21060333.